News
To stay updated on Sygnature’s achievements, customer collaborations, and prestigious awards, read our current press releases and explore the latest developments at Sygnature Discovery.
To stay updated on Sygnature’s achievements, customer collaborations, and prestigious awards, read our current press releases and explore the latest developments at Sygnature Discovery.
Filter by:
10th October 2023
News
Sygnature Discovery collaborates with Axol Bioscience to utilize human iPSC-derived microglial cells in high-content imaging drug discovery screening workflows.
25th September 2023
News Targeted Protein Degradation
Sygnature Discovery and UBE Corporation successfully identify potent SHP2 degrader compounds
14th September 2023
News
Sygnature Discovery’s hit finding expertise in high demand as cardiac biotech customer, River BioMedics, receives an additional €2M seed investment
31st July 2023
News
Sygnature Discovery accelerates global growth with major North American acquisition
12th June 2023
News
Sygnature Discovery launches its in vivo LPS model to profile early-stage anti-inflammatory drugs
18th April 2023
News
Sygnature Discovery and Daewoong Pharma announce research collaboration
7th March 2023
News
New platform set to accelerate early-stage targeted protein degradation
17th January 2023
News
Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities
22nd December 2022
News
Sygnature Discovery partners the Oncology Development Programme (ODP2) to find UK-based breakthroughs in Oncology
10th May 2022
News
Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’
26th April 2022
News
Sygnature Discovery acquires Peak Proteins
24th March 2022
News
500 – and counting!